JP2022546699A5 - - Google Patents

Info

Publication number
JP2022546699A5
JP2022546699A5 JP2022513157A JP2022513157A JP2022546699A5 JP 2022546699 A5 JP2022546699 A5 JP 2022546699A5 JP 2022513157 A JP2022513157 A JP 2022513157A JP 2022513157 A JP2022513157 A JP 2022513157A JP 2022546699 A5 JP2022546699 A5 JP 2022546699A5
Authority
JP
Japan
Application number
JP2022513157A
Other languages
Japanese (ja)
Other versions
JPWO2021042060A5 (https=
JP7708436B2 (ja
JP2022546699A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/048962 external-priority patent/WO2020047353A1/en
Priority claimed from PCT/US2019/048953 external-priority patent/WO2020047344A1/en
Application filed filed Critical
Priority claimed from PCT/US2020/048823 external-priority patent/WO2021042060A1/en
Publication of JP2022546699A publication Critical patent/JP2022546699A/ja
Publication of JPWO2021042060A5 publication Critical patent/JPWO2021042060A5/ja
Publication of JP2022546699A5 publication Critical patent/JP2022546699A5/ja
Priority to JP2025069544A priority Critical patent/JP2025111590A/ja
Application granted granted Critical
Publication of JP7708436B2 publication Critical patent/JP7708436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022513157A 2019-08-30 2020-08-31 核酸を細胞に送達するための組成物および方法 Active JP7708436B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025069544A JP2025111590A (ja) 2019-08-30 2025-04-21 核酸を細胞に送達するための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
USPCT/US2019/048953 2019-08-30
PCT/US2019/048962 WO2020047353A1 (en) 2018-08-31 2019-08-30 Compositions and methods for enhancing triplex and nuclease-based gene editing
PCT/US2019/048953 WO2020047344A1 (en) 2018-08-31 2019-08-30 Compositions and methods for enhancing donor oligonucleotide-based gene editing
USPCT/US2019/048962 2019-08-30
US201962944281P 2019-12-05 2019-12-05
US62/944,281 2019-12-05
PCT/US2020/048823 WO2021042060A1 (en) 2019-08-30 2020-08-31 Compositions and methods for delivery of nucleic acids to cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025069544A Division JP2025111590A (ja) 2019-08-30 2025-04-21 核酸を細胞に送達するための組成物および方法

Publications (4)

Publication Number Publication Date
JP2022546699A JP2022546699A (ja) 2022-11-07
JPWO2021042060A5 JPWO2021042060A5 (https=) 2023-09-08
JP2022546699A5 true JP2022546699A5 (https=) 2023-09-08
JP7708436B2 JP7708436B2 (ja) 2025-07-15

Family

ID=74684750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513157A Active JP7708436B2 (ja) 2019-08-30 2020-08-31 核酸を細胞に送達するための組成物および方法
JP2025069544A Pending JP2025111590A (ja) 2019-08-30 2025-04-21 核酸を細胞に送達するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025069544A Pending JP2025111590A (ja) 2019-08-30 2025-04-21 核酸を細胞に送達するための組成物および方法

Country Status (13)

Country Link
US (7) US12485180B2 (https=)
EP (1) EP4021496B1 (https=)
JP (2) JP7708436B2 (https=)
KR (1) KR20220101073A (https=)
CN (1) CN115151275A (https=)
AU (1) AU2020336992A1 (https=)
CA (1) CA3149421A1 (https=)
DK (1) DK4021496T3 (https=)
FI (1) FI4021496T3 (https=)
IL (1) IL290862A (https=)
LT (1) LT4021496T (https=)
MX (1) MX2022002342A (https=)
WO (1) WO2021042060A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7570107B2 (ja) 2018-08-31 2024-10-21 イェール ユニバーシティー ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
CA3193424A1 (en) * 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
CN117295753A (zh) * 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
MX2023006403A (es) * 2020-12-04 2023-08-09 Gennao Bio Inc Composiciones y métodos para el suministro de ácidos nucleicos a las células.
US20240216530A1 (en) * 2021-03-03 2024-07-04 Yale University Compositions and Methods for Treating Skeletal Muscle Disease
EP4346907A4 (en) * 2021-05-25 2025-06-25 Transmab Pty Ltd ENHANCED IMMUNOGLOBULIN I
JP2024527322A (ja) * 2021-07-02 2024-07-24 イエール ユニバーシティ がんを治療するための組成物および方法
CN117979994A (zh) * 2021-07-08 2024-05-03 天普大学-联邦高等教育系统 用于增加靶基因和蛋白质的表达的寡核苷酸和病毒未转译区(utr)
WO2023034864A1 (en) * 2021-08-31 2023-03-09 Yale University Compositions and methods for treating cancers
WO2023168427A1 (en) * 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023168401A1 (en) * 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
KR20250137203A (ko) * 2022-12-27 2025-09-17 예일 유니버시티 항체 약물 접합체
WO2024140936A1 (en) * 2022-12-30 2024-07-04 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Humanized cell-penetrating antibodies
WO2024158824A1 (en) * 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
WO2025049905A1 (en) * 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US6441130B1 (en) 1991-05-24 2002-08-27 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
JPH09503644A (ja) 1993-06-25 1997-04-15 エール ユニバーシティ 部位特異的変異誘発のための化学的に修飾されたオリゴヌクレオチド
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
WO1996039195A2 (en) 1995-06-06 1996-12-12 Yale University Chemically modified oligonucleotide for site-directed mutagenesis
US7279463B2 (en) 1995-06-07 2007-10-09 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
WO1996040271A1 (en) 1995-06-07 1996-12-19 Yale University Treatment of hemoglobinopathies
WO1997032602A1 (en) 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6326479B1 (en) 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
AU5886000A (en) 1999-06-25 2001-01-31 Northwestern University Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
US6919208B2 (en) 2000-05-22 2005-07-19 The Children's Hospital Of Philadelphia Methods and compositions for enhancing the delivery of a nucleic acid to a cell
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7067617B2 (en) 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
US20040197892A1 (en) 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
WO2002094983A2 (en) 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
EP1468086A2 (en) 2001-12-14 2004-10-20 Yale University INTRACELLULAR GENERATION OF SINGLE−STRANDED DNA
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
JP2009520463A (ja) 2005-11-28 2009-05-28 ザ スクリプス リサーチ インスティテュート Tnnのための亜鉛フィンガー結合ドメイン
WO2007081647A2 (en) 2006-01-03 2007-07-19 The Scripps Research Institute Zinc finger domains specifically binding agc
CN1986792A (zh) 2006-12-14 2007-06-27 方炳良 致病细胞的外来抗原标记方法
JP2010515464A (ja) 2007-01-11 2010-05-13 イエール・ユニバーシテイ Hiv細胞表面受容体の標的化不活性化のための組成物および方法
WO2008091911A2 (en) 2007-01-22 2008-07-31 The Regents Of The University Of California Use of antibody conjugates
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
US8609615B2 (en) * 2008-10-15 2013-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of myotonic dystrophy
US8309356B2 (en) 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
WO2010123983A1 (en) 2009-04-21 2010-10-28 Yale University Compostions and methods for targeted gene therapy
US9155801B2 (en) * 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
US20110268810A1 (en) 2009-11-02 2011-11-03 Yale University Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
EP3597665A1 (en) * 2011-04-01 2020-01-22 Yale University, Inc. Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair
CN107164330A (zh) 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
EP3428287B1 (en) 2011-04-08 2021-03-24 Carnegie Mellon University Conformationally-preorganized, minipeg-containing gamma-peptide nucleic acids
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US9272043B2 (en) 2011-12-02 2016-03-01 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9732146B2 (en) 2012-03-30 2017-08-15 The United States Of America As Represented By The Department Of Veterans Affairs Antibody-mediated transduction of heat shock proteins into living cells
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US20150290244A1 (en) 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
KR102530118B1 (ko) 2012-07-25 2023-05-08 더 브로드 인스티튜트, 인코퍼레이티드 유도 dna 결합 단백질 및 게놈 교란 도구 및 이의 적용
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
EP3094646B1 (en) 2014-01-13 2020-04-15 Valerion Therapeutics, LLC Internalizing moieties
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
BR112016019940A2 (pt) 2014-03-21 2017-10-24 Univ Leland Stanford Junior edição de genoma sem nucleases
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US10202591B2 (en) 2014-06-13 2019-02-12 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
EP3194450A1 (en) 2014-08-28 2017-07-26 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
WO2016081621A1 (en) 2014-11-18 2016-05-26 Yale University Formulations for targeted release of agents under low ph conditions and methods of use thereof
WO2017015101A1 (en) 2015-07-17 2017-01-26 University Of Washington Methods for maximizing the efficiency of targeted gene correction
EP3325505B1 (en) 2015-07-23 2020-08-19 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
CN108473982A (zh) 2015-12-24 2018-08-31 思兰克斯有限公司 用于蛋白生产的改进的真核细胞及其制备方法
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
JP2019513371A (ja) * 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
CN109803687B (zh) 2016-06-15 2022-11-15 耶鲁大学 纳米载体向肿瘤的抗体介导的自催化靶向递送
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
EP3655432A4 (en) 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd BINDING PROTEINS 1
US20200323964A1 (en) 2017-10-16 2020-10-15 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of mrna
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
WO2019152808A1 (en) 2018-02-01 2019-08-08 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
JP7570107B2 (ja) 2018-08-31 2024-10-21 イェール ユニバーシティー ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
SG11202101984PA (en) 2018-08-31 2021-03-30 Univ Yale Compositions and methods for enhancing triplex and nuclease-based gene editing
FI20186112A1 (en) 2018-12-19 2020-06-20 Actim Oy System and method for analysing a point-of-care test result
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
CN111218458B (zh) 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
CA3193424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
MX2023006403A (es) 2020-12-04 2023-08-09 Gennao Bio Inc Composiciones y métodos para el suministro de ácidos nucleicos a las células.
WO2023168352A1 (en) 2022-03-03 2023-09-07 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof

Similar Documents

Publication Publication Date Title
JP2022546699A5 (https=)
CN305536197S (https=)
CN306031062S (https=)
CN305532850S (https=)
CN305532624S (https=)
CN305530841S (https=)
CN305529606S (https=)
CN305529534S (https=)
CN305529170S (https=)
CN305529163S (https=)
CN305528780S (https=)
CN306800944S (https=)
CN305994331S (https=)
CN306381828S (https=)
CN306381612S (https=)
CN306381201S (https=)
CN306381116S (https=)
CN306331647S (https=)
CN306331281S (https=)
CN306282171S (https=)
CN306281376S (https=)
CN306245985S (https=)
CN306245383S (https=)
CN306243430S (https=)
CN306238998S (https=)